Forty Seven initiated with a Buy at Guggenheim. Guggenheim analyst Michael Schmidt started Forty Seven with a Buy rating and $25 price target. The company is the scientific and clinical leader in targeting CD47, a novel mechanistic approach with “significant” market potential if successful, Schmidt tells investors in a research note. The analyst believes multiple early clinical-phase data readouts through 2019 may establish proof-of-concept in additional tumor types.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.